News for December 2010

News Archive

Why Reindeer Love Magic Mushrooms Why Reindeer Love Magic Mushrooms

Santa needs to ensure Rudolph is kept on the straight and narrow this Christmas if all the presents are to be delivered on time.

First Effective Non-Opioid Treatment in Two Decades Could be Available Within Two Years First Effective Non-Opioid Treatment in Two Decades Could be Available Within Two Years

A breakthrough drug containing theobromine, an ingredient naturally present in cocoa and chocolate, is entering the final stages of human clinical trials for the treatment of persistent cough, researchers announced today. The drug is being jointly developed by SEEK, a leading UK privately-owned drug-discovery group, and could be on the market within two years.

Scientists strive to make new drugs ‘like house guests from hell’ Scientists strive to make new drugs ‘like house guests from hell’

Designing drugs to be like house guests from hell – reluctant to leave, despite their host’s best efforts - may hold the key to more effective treatment of cancers and brain diseases like Alzheimer's.

Aesica Announces European Expansion And Long Term Strategic Partnership Aesica Announces European Expansion And Long Term Strategic Partnership

Aesica Pharmaceuticals has today announced (15th December 2010) that it has signed contracts ahead of acquiring three manufacturing sites in Germany andItaly

Horizon Discovery to Support 50 Centers of Excellence in Human Cellular Gene-Editing Horizon Discovery to Support 50 Centers of Excellence in Human Cellular Gene-Editing

Company will provide open access to its rAAV GENESIS human gene-editing platform as part of strategy to generate 2500 new in vitro models of cancer, neurodegenerative cardiovascular and infectious diseases.

New Data Suggest a Potential Role for AT9283 in Combination With Lenalidomide and With Docetaxel in the Treatment of Multiple Myeloma and Non-Hodgkin’s Lymphoma New Data Suggest a Potential Role for AT9283 in Combination With Lenalidomide and With Docetaxel in the Treatment of Multiple Myeloma and Non-Hodgkin’s Lymphoma

Astex Therapeutics, the UK-based biotechnology company developing targeted therapies for oncology and virology, today announced presentations of new data on its combinatorial oncogenic kinase inhibitor AT9283. The presentations will be made during the 52nd American Society of Hematology Meeting, 4-7th December in Orlando.

New treatments for stroke, hypertension and heart disease under microscope New treatments for stroke, hypertension and heart disease under microscope

Potential new ways of treating people suffering from high blood pressure, stoke and heart disease, will be highlighted at a major international gathering of pharmacologists in London.

Bioventix develops novel antibody to Vitamin D Bioventix develops novel antibody to Vitamin D

Vitamin D status is linked with increased risk of many chronic diseases including autoimmune diseases, cardiovascular disease, cancers, type II diabetes and infectious diseases. This new awareness of the importance of vitamin D to overall health and the consequences of vitamin D deficiency has stimulated rapid growth in the demand for vitamin D tests at hospitals and clinics. Consequently, antibodies for use in such diagnostic tests are highly sought after within the healthcare industry.